<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36873252</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1322</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Cancer management and research</Title><ISOAbbreviation>Cancer Manag Res</ISOAbbreviation></Journal><ArticleTitle>Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>255</EndPage><MedlinePgn>245-255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/CMAR.S400013</ELocationID><Abstract><AbstractText>Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL). With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL.</AbstractText><CopyrightInformation>&#xa9; 2023 Zhang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Baoan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Cancer Manag Res</MedlineTA><NlmUniqueID>101512700</NlmUniqueID><ISSNLinking>1179-1322</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAR-T therapy</Keyword><Keyword MajorTopicYN="N">CD47</Keyword><Keyword MajorTopicYN="N">NF-&#x3ba;B</Keyword><Keyword MajorTopicYN="N">antibody drug-conjugate</Keyword><Keyword MajorTopicYN="N">drug resistance</Keyword><Keyword MajorTopicYN="N">relapse and refractory DLBCL</Keyword><Keyword MajorTopicYN="N">targeted therapy</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36873252</ArticleId><ArticleId IdType="pmc">PMC9976586</ArticleId><ArticleId IdType="doi">10.2147/CMAR.S400013</ArticleId><ArticleId IdType="pii">400013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275&#x2013;282. doi:10.1182/blood-2003-05-1545</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-05-1545</ArticleId><ArticleId IdType="pubmed">14504078</ArticleId></ArticleIdList></Reference><Reference><Citation>Klener P, Klanova M. Drug resistance in non-Hodgkin lymphomas. Int J Mol Sci. 2020;21(6):2081. doi:10.3390/ijms21062081</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21062081</ArticleId><ArticleId IdType="pmc">PMC7139754</ArticleId><ArticleId IdType="pubmed">32197371</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375&#x2013;2390. doi:10.1182/blood-2016-01-643569</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-01-643569</ArticleId><ArticleId IdType="pmc">PMC4874220</ArticleId><ArticleId IdType="pubmed">26980727</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381&#x2013;1387. doi:10.1038/s41588-018-0204-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0204-y</ArticleId><ArticleId IdType="pmc">PMC6168352</ArticleId><ArticleId IdType="pubmed">30224644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornecker LM, Muller L, Bertrand F, et al. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci Rep. 2019;9(1):895. doi:10.1038/s41598-018-37273-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-37273-4</ArticleId><ArticleId IdType="pmc">PMC6351558</ArticleId><ArticleId IdType="pubmed">30696890</ArticleId></ArticleIdList></Reference><Reference><Citation>Solimando AG, Annese T, Tamma R, et al. New insights into diffuse large B-cell lymphoma pathobiology. Cancers. 2020;12(7):1869. doi:10.3390/cancers12071869</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12071869</ArticleId><ArticleId IdType="pmc">PMC7408689</ArticleId><ArticleId IdType="pubmed">32664527</ArticleId></ArticleIdList></Reference><Reference><Citation>Del PA, Schioppa T, Tiberio L, et al. Leukocyte trafficking in tumor microenvironment. Curr Opin Pharmacol. 2017;35:40&#x2013;47. doi:10.1016/j.coph.2017.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2017.05.004</ArticleId><ArticleId IdType="pubmed">28577499</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74&#x2013;80. doi:10.1126/science.aaa6204</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa6204</ArticleId><ArticleId IdType="pubmed">25838376</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorovic BM, Jelicic J, Mihaljevic B, et al. Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses. Int J Mol Sci. 2016;17(5):683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881509</ArticleId><ArticleId IdType="pubmed">27164089</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li LR. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. Chin Med J. 2020;134(3):253&#x2013;260. doi:10.1097/CM9.0000000000001294</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001294</ArticleId><ArticleId IdType="pmc">PMC7846449</ArticleId><ArticleId IdType="pubmed">33323828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu-Monette ZY, Xiao M, Au Q, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res. 2019;7(4):644&#x2013;657. doi:10.1158/2326-6066.CIR-18-0439</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0439</ArticleId><ArticleId IdType="pubmed">30745366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwstra R, He Y, de Boer J, et al. CD47 expression defines efficacy of rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) diffuse large B-cell Lymphoma Patients (DLBCL), but not in GCB DLBCL. Cancer Immunol Res. 2019;7(10):1663&#x2013;1671. doi:10.1158/2326-6066.CIR-18-0781</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0781</ArticleId><ArticleId IdType="pubmed">31409608</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito A, Delamain MT, Fanelli MF, et al. Angiogenesis&#x2019; related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients. Tumour Biol. 2021;43(1):129&#x2013;140. doi:10.3233/TUB-211510</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/TUB-211510</ArticleId><ArticleId IdType="pubmed">34219681</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248&#x2013;1264. doi:10.1016/j.cell.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId><ArticleId IdType="pmc">PMC6410740</ArticleId><ArticleId IdType="pubmed">30849371</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahini L, Gasparov S, Petrusevska G, et al. Clinical significance of VEGF-A and microvessel density in diffuse large B-Cell lymphoma and low-grade follicular lymphoma. Acta Clin Croat. 2017;56(4):588&#x2013;593. doi:10.20471/acc.2017.56.04.02</Citation><ArticleIdList><ArticleId IdType="doi">10.20471/acc.2017.56.04.02</ArticleId><ArticleId IdType="pubmed">29590710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang W, Zhou H, Qin Y, et al. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era. Int J Hematol. 2021;114(2):189&#x2013;198. doi:10.1007/s12185-021-03145-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-021-03145-3</ArticleId><ArticleId IdType="pubmed">33893987</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: aVAil. J Clin Oncol. 2009;27(8):1227&#x2013;1234. doi:10.1200/JCO.2007.14.5466</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2007.14.5466</ArticleId><ArticleId IdType="pubmed">19188680</ArticleId></ArticleIdList></Reference><Reference><Citation>Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539&#x2013;1544. doi:10.1200/JCO.2006.09.6305</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.09.6305</ArticleId><ArticleId IdType="pubmed">17442997</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour JF, Pfreundschuh M, Trneny M, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99(8):1343&#x2013;1349. doi:10.3324/haematol.2013.100818</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2013.100818</ArticleId><ArticleId IdType="pmc">PMC4116833</ArticleId><ArticleId IdType="pubmed">24895339</ArticleId></ArticleIdList></Reference><Reference><Citation>Young RM, Phelan JD, Wilson WH, et al. Pathogenic B-cell receptor signaling in lymphoid malignancies: new insights to improve treatment. Immunol Rev. 2019;291(1):190&#x2013;213. doi:10.1111/imr.12792</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12792</ArticleId><ArticleId IdType="pmc">PMC6693651</ArticleId><ArticleId IdType="pubmed">31402495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577. doi:10.3389/fonc.2020.591577</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.591577</ArticleId><ArticleId IdType="pmc">PMC7116322</ArticleId><ArticleId IdType="pubmed">33154951</ArticleId></ArticleIdList></Reference><Reference><Citation>Young RM, Shaffer AR, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77&#x2013;85. doi:10.1053/j.seminhematol.2015.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2015.01.008</ArticleId><ArticleId IdType="pmc">PMC4374122</ArticleId><ArticleId IdType="pubmed">25805587</ArticleId></ArticleIdList></Reference><Reference><Citation>Turturro F. Constitutive NF- &#x3ba; B activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma. Biomed Res Int. 2015;2015:484537. doi:10.1155/2015/484537</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/484537</ArticleId><ArticleId IdType="pmc">PMC4423017</ArticleId><ArticleId IdType="pubmed">25984532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676&#x2013;1679. doi:10.1126/science.1153629</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153629</ArticleId><ArticleId IdType="pubmed">18323416</ArticleId></ArticleIdList></Reference><Reference><Citation>Juilland M, Thome M. Holding all the CARDs: how MALT1 controls CARMA/CARD-dependent signaling. Front Immunol. 2018;9:1927. doi:10.3389/fimmu.2018.01927</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01927</ArticleId><ArticleId IdType="pmc">PMC6125328</ArticleId><ArticleId IdType="pubmed">30214442</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunleavy K, Erdmann T, Lenz G. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Cancer Treat Rev. 2018;65:41&#x2013;46. doi:10.1016/j.ctrv.2018.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2018.01.002</ArticleId><ArticleId IdType="pubmed">29549872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontan L, Goldstein R, Casalena G, et al. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021;137(6):788&#x2013;800. doi:10.1182/blood.2019004713</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019004713</ArticleId><ArticleId IdType="pmc">PMC7885826</ArticleId><ArticleId IdType="pubmed">32785655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducharme O, Beylot-Barry M, Pham-Ledard A, et al. Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg type. J Invest Dermatol. 2019;139(11):2334&#x2013;2342. doi:10.1016/j.jid.2019.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2019.05.008</ArticleId><ArticleId IdType="pubmed">31150604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabizon R, London N. Fast and clean BTK inhibitor. J Med Chem. 2020. 63. 10:5100&#x2013;5101. doi:10.1021/acs.jmedchem.0c00597</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00597</ArticleId><ArticleId IdType="pmc">PMC7304894</ArticleId><ArticleId IdType="pubmed">32401033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou K, Yu Z, Jia Y, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol Hematol. 2020;152:103010. doi:10.1016/j.critrevonc.2020.103010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2020.103010</ArticleId><ArticleId IdType="pubmed">32540781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922&#x2013;926. doi:10.1038/nm.3884</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3884</ArticleId><ArticleId IdType="pmc">PMC8372245</ArticleId><ArticleId IdType="pubmed">26193343</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes A, Sehn LH, Johnson P, et al. Randomized Phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in Non-Germinal Center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285&#x2013;1295. doi:10.1200/JCO.18.02403</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.02403</ArticleId><ArticleId IdType="pmc">PMC6553835</ArticleId><ArticleId IdType="pubmed">30901302</ArticleId></ArticleIdList></Reference><Reference><Citation>George B, Chowdhury SM, Hart A, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers. 2020;12(5):1328. doi:10.3390/cancers12051328</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12051328</ArticleId><ArticleId IdType="pmc">PMC7281539</ArticleId><ArticleId IdType="pubmed">32455989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80. doi:10.1186/s13045-016-0313-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-016-0313-y</ArticleId><ArticleId IdType="pmc">PMC5010774</ArticleId><ArticleId IdType="pubmed">27590878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio AJ, Bencomo-Alvarez AE, Young JE, et al. 26S proteasome Non-ATPase regulatory subunits 1 (PSMD1) and 3 (PSMD3) as putative targets for cancer prognosis and therapy. Cells. 2021;10(9):2390. doi:10.3390/cells10092390</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10092390</ArticleId><ArticleId IdType="pmc">PMC8472613</ArticleId><ArticleId IdType="pubmed">34572038</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z, Chen X, Li Z, et al. The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Ann Hematol. 2018;97(11):2137&#x2013;2144. doi:10.1007/s00277-018-3435-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-018-3435-1</ArticleId><ArticleId IdType="pubmed">30027435</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, Phase 3 trial. Lancet Oncol. 2019;20(5):649&#x2013;662. doi:10.1016/S1470-2045(18)30935-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(18)30935-5</ArticleId><ArticleId IdType="pmc">PMC6494978</ArticleId><ArticleId IdType="pubmed">30948276</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Chen J, Tamayo AT, et al. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018;9(1):346&#x2013;360. doi:10.18632/oncotarget.20378</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.20378</ArticleId><ArticleId IdType="pmc">PMC5787470</ArticleId><ArticleId IdType="pubmed">29416618</ArticleId></ArticleIdList></Reference><Reference><Citation>Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826&#x2013;833. doi:10.1200/JCO.2016.70.4320</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2016.70.4320</ArticleId><ArticleId IdType="pmc">PMC5455685</ArticleId><ArticleId IdType="pubmed">28095146</ArticleId></ArticleIdList></Reference><Reference><Citation>Morschhauser F, Feugier P, Flinn IW, et al. A Phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600&#x2013;609. doi:10.1182/blood.2020006578</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006578</ArticleId><ArticleId IdType="pmc">PMC7869186</ArticleId><ArticleId IdType="pubmed">33538797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bykov V, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89&#x2013;102. doi:10.1038/nrc.2017.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2017.109</ArticleId><ArticleId IdType="pubmed">29242642</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986&#x2013;3996. doi:10.1182/blood-2012-05-433334</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-05-433334</ArticleId><ArticleId IdType="pmc">PMC3496956</ArticleId><ArticleId IdType="pubmed">22955915</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene. 2018;37(14):1830&#x2013;1844. doi:10.1038/s41388-017-0111-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-017-0111-1</ArticleId><ArticleId IdType="pubmed">29353886</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008&#x2013;2016. doi:10.1056/NEJMct1114348</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMct1114348</ArticleId><ArticleId IdType="pubmed">22621628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Waschke BC, Woolaver RA, et al. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. 2020;11(7):472&#x2013;482. doi:10.1007/s13238-020-00694-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-020-00694-x</ArticleId><ArticleId IdType="pmc">PMC7305292</ArticleId><ArticleId IdType="pubmed">32162275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sermer D, Pasqualucci L, Wendel HG, et al. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494&#x2013;507. doi:10.1038/s41571-019-0190-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-019-0190-8</ArticleId><ArticleId IdType="pmc">PMC6650343</ArticleId><ArticleId IdType="pubmed">30837715</ArticleId></ArticleIdList></Reference><Reference><Citation>de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134&#x2013;147. doi:10.1016/j.ejca.2016.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2016.09.010</ArticleId><ArticleId IdType="pubmed">27755997</ArticleId></ArticleIdList></Reference><Reference><Citation>de Charette M, Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018;103(8):1256&#x2013;1268. doi:10.3324/haematol.2017.184192</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.184192</ArticleId><ArticleId IdType="pmc">PMC6068015</ArticleId><ArticleId IdType="pubmed">30006449</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? Oncoimmunology. 2017;6(4):e1295202. doi:10.1080/2162402X.2017.1295202</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2017.1295202</ArticleId><ArticleId IdType="pmc">PMC5414870</ArticleId><ArticleId IdType="pubmed">28507804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Ortega-Molina A, Geng H, et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 2017;7(1):38&#x2013;53. doi:10.1158/2159-8290.CD-16-0975</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-16-0975</ArticleId><ArticleId IdType="pmc">PMC5300005</ArticleId><ArticleId IdType="pubmed">27733359</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S, Hu Q, Zhang H, et al. HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of Anti-PD-L1 therapy. Mol Cancer Ther. 2019;18(5):900&#x2013;908. doi:10.1158/1535-7163.MCT-18-1068</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.MCT-18-1068</ArticleId><ArticleId IdType="pubmed">30824609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cycon KA, Mulvaney K, Rimsza LM, et al. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013;140(2):259&#x2013;272. doi:10.1111/imm.12136</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12136</ArticleId><ArticleId IdType="pmc">PMC3784172</ArticleId><ArticleId IdType="pubmed">23789844</ArticleId></ArticleIdList></Reference><Reference><Citation>Frys S, Simons Z, Hu Q, et al. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol. 2015;169(4):506&#x2013;519. doi:10.1111/bjh.13318</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.13318</ArticleId><ArticleId IdType="pmc">PMC5802357</ArticleId><ArticleId IdType="pubmed">25712263</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Cai Y, Yang Y, et al. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma. J Pathol. 2018;246(2):141&#x2013;153. doi:10.1002/path.5108</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5108</ArticleId><ArticleId IdType="pubmed">29876933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Li D, Zhou J. Histone deacetylase 6 as a therapeutic target in B cell-associated hematological malignancies. Front Pharmacol. 2020;11:971. doi:10.3389/fphar.2020.00971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00971</ArticleId><ArticleId IdType="pmc">PMC7333221</ArticleId><ArticleId IdType="pubmed">32676030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrowicz M, Dwojak M, Pyrzynska B, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017;130(14):1628&#x2013;1638. doi:10.1182/blood-2016-08-736066</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-08-736066</ArticleId><ArticleId IdType="pubmed">28830887</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Li X, Zang J, et al. Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Med Chem. 2017;17(6):802&#x2013;812. doi:10.2174/1871520616666160901150427</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871520616666160901150427</ArticleId><ArticleId IdType="pubmed">27592546</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan XW, Wang HQ, Ban WW, et al. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020;11(1):20. doi:10.1038/s41419-019-2210-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-2210-0</ArticleId><ArticleId IdType="pmc">PMC6944697</ArticleId><ArticleId IdType="pubmed">31907371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Kim UJ, Yoo HY, et al. Anti-cancer effects of CKD-581, a potent histone deacetylase inhibitor against diffuse large B-cell lymphoma. Int J Mol Sci. 2020;21(12):4377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352247</ArticleId><ArticleId IdType="pubmed">32575557</ArticleId></ArticleIdList></Reference><Reference><Citation>Persky DO, Li H, Rimsza LM, et al. A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol. 2018;93(4):486&#x2013;493. doi:10.1002/ajh.25010</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25010</ArticleId><ArticleId IdType="pmc">PMC5842116</ArticleId><ArticleId IdType="pubmed">29266344</ArticleId></ArticleIdList></Reference><Reference><Citation>Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185&#x2013;194. doi:10.1182/blood-2016-02-699520</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-02-699520</ArticleId><ArticleId IdType="pmc">PMC4972610</ArticleId><ArticleId IdType="pubmed">27166360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37(Suppl 1):95&#x2013;100. doi:10.1002/hon.2591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2591</ArticleId><ArticleId IdType="pubmed">31187533</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29&#x2013;33. doi:10.1016/j.tmrv.2019.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2019.08.003</ArticleId><ArticleId IdType="pubmed">31677848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopfinger G, Jager U, Worel N. CAR-T cell therapy in diffuse large B cell lymphoma: hype and hope. Hemasphere. 2019;3(2):e185. doi:10.1097/HS9.0000000000000185</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000185</ArticleId><ArticleId IdType="pmc">PMC6746029</ArticleId><ArticleId IdType="pubmed">31723824</ArticleId></ArticleIdList></Reference><Reference><Citation>Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507&#x2013;1517. doi:10.1056/NEJMoa1407222</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1407222</ArticleId><ArticleId IdType="pmc">PMC4267531</ArticleId><ArticleId IdType="pubmed">25317870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45&#x2013;55. doi:10.1016/j.blre.2018.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2018.11.002</ArticleId><ArticleId IdType="pmc">PMC6628697</ArticleId><ArticleId IdType="pubmed">30528964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294&#x2013;2308. doi:10.1016/S0140-6736(22)00662-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00662-6</ArticleId><ArticleId IdType="pubmed">35717989</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45&#x2013;56. doi:10.1056/NEJMoa1804980</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1804980</ArticleId><ArticleId IdType="pubmed">30501490</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403&#x2013;1415. doi:10.1016/S1470-2045(21)00375-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00375-2</ArticleId><ArticleId IdType="pubmed">34516954</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531&#x2013;2544. doi:10.1056/NEJMoa1707447</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707447</ArticleId><ArticleId IdType="pmc">PMC5882485</ArticleId><ArticleId IdType="pubmed">29226797</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, Phase 1&#x2013;2 trial. Lancet Oncol. 2019;20(1):31&#x2013;42. doi:10.1016/S1470-2045(18)30864-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(18)30864-7</ArticleId><ArticleId IdType="pmc">PMC6733402</ArticleId><ArticleId IdType="pubmed">30518502</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640&#x2013;654. doi:10.1056/NEJMoa2116133</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116133</ArticleId><ArticleId IdType="pubmed">34891224</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735&#x2013;742. doi:10.1038/s41591-022-01731-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01731-4</ArticleId><ArticleId IdType="pmc">PMC9018426</ArticleId><ArticleId IdType="pubmed">35314842</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629&#x2013;639. doi:10.1056/NEJMoa2116596</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116596</ArticleId><ArticleId IdType="pubmed">34904798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372&#x2013;385. doi:10.1038/s41571-019-0184-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-019-0184-6</ArticleId><ArticleId IdType="pmc">PMC8214555</ArticleId><ArticleId IdType="pubmed">30837712</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalabi H, Kraft IL, Wang HW, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica. 2018;103(5):e215&#x2013;e218. doi:10.3324/haematol.2017.183459</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.183459</ArticleId><ArticleId IdType="pmc">PMC5927974</ArticleId><ArticleId IdType="pubmed">29419431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282&#x2013;1295. doi:10.1158/2159-8290.CD-15-1020</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-15-1020</ArticleId><ArticleId IdType="pmc">PMC4670800</ArticleId><ArticleId IdType="pubmed">26516065</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Zhao L, Zhang Y, et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol. 2019;9:1237. doi:10.3389/fonc.2019.01237</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.01237</ArticleId><ArticleId IdType="pmc">PMC6882288</ArticleId><ArticleId IdType="pubmed">31824840</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203&#x2013;220. doi:10.1038/nrclinonc.2016.168</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2016.168</ArticleId><ArticleId IdType="pubmed">27805626</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019;133(21):2279&#x2013;2290. doi:10.1182/blood-2018-10-879015</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-10-879015</ArticleId><ArticleId IdType="pmc">PMC6911840</ArticleId><ArticleId IdType="pubmed">30910787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, Phase II study. J Clin Oncol. 2019;37(6):481&#x2013;489. doi:10.1200/JCO.18.00766</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.18.00766</ArticleId><ArticleId IdType="pmc">PMC6528729</ArticleId><ArticleId IdType="pubmed">30620669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J Clin Oncol. 2016;34(23):2698&#x2013;2704. doi:10.1200/JCO.2015.65.9789</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2015.65.9789</ArticleId><ArticleId IdType="pmc">PMC5019749</ArticleId><ArticleId IdType="pubmed">27269947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Fan Y, Li M, et al. Therapy strategy of CD47 in diffuse large B-cell lymphoma (DLBCL). Dis Markers. 2021;2021:4894022. doi:10.1155/2021/4894022</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/4894022</ArticleId><ArticleId IdType="pmc">PMC8463246</ArticleId><ArticleId IdType="pubmed">34567285</ArticleId></ArticleIdList></Reference><Reference><Citation>Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin&#x2019;s lymphoma. N Engl J Med. 2018;379(18):1711&#x2013;1721. doi:10.1056/NEJMoa1807315</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1807315</ArticleId><ArticleId IdType="pmc">PMC8058634</ArticleId><ArticleId IdType="pubmed">30380386</ArticleId></ArticleIdList></Reference><Reference><Citation>Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389&#x2013;6397. doi:10.1158/1078-0432.CCR-11-1417</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1417</ArticleId><ArticleId IdType="pubmed">22003066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155&#x2013;165. doi:10.1200/JCO.19.00172</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.00172</ArticleId><ArticleId IdType="pmc">PMC7032881</ArticleId><ArticleId IdType="pubmed">31693429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351&#x2013;363. doi:10.1056/NEJMoa2115304</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115304</ArticleId><ArticleId IdType="pmc">PMC11702892</ArticleId><ArticleId IdType="pubmed">34904799</ArticleId></ArticleIdList></Reference><Reference><Citation>Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022;13:1554005271. doi:10.1177/20406207221087511</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406207221087511</ArticleId><ArticleId IdType="pmc">PMC8943462</ArticleId><ArticleId IdType="pubmed">35340719</ArticleId></ArticleIdList></Reference><Reference><Citation>Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790&#x2013;800. doi:10.1016/S1470-2045(21)00139-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00139-X</ArticleId><ArticleId IdType="pubmed">33989558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11(4):68. doi:10.1038/s41408-021-00456-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00456-w</ArticleId><ArticleId IdType="pmc">PMC8021545</ArticleId><ArticleId IdType="pubmed">33820908</ArticleId></ArticleIdList></Reference><Reference><Citation>Salles G, Duell J, Gonzalez BE, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978&#x2013;988. doi:10.1016/S1470-2045(20)30225-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30225-4</ArticleId><ArticleId IdType="pubmed">32511983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez BE. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. Front Immunol. 2022;13:909008. doi:10.3389/fimmu.2022.909008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.909008</ArticleId><ArticleId IdType="pmc">PMC9344863</ArticleId><ArticleId IdType="pubmed">35928819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawalha Y. Relapsed/refractory diffuse large B-cell lymphoma: a look at the approved and emerging therapies. J Pers Med. 2021;11(12):1345. doi:10.3390/jpm11121345</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11121345</ArticleId><ArticleId IdType="pmc">PMC8708171</ArticleId><ArticleId IdType="pubmed">34945817</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedrosa L, Fernandez-Miranda I, Perez-Callejo D, et al. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Sci Rep. 2021;11(1):1886. doi:10.1038/s41598-020-80376-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80376-0</ArticleId><ArticleId IdType="pmc">PMC7820010</ArticleId><ArticleId IdType="pubmed">33479306</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396&#x2013;1407. doi:10.1056/NEJMoa1801445</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1801445</ArticleId><ArticleId IdType="pmc">PMC6010183</ArticleId><ArticleId IdType="pubmed">29641966</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551&#x2013;568. doi:10.1016/j.ccell.2020.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.03.015</ArticleId><ArticleId IdType="pmc">PMC8459709</ArticleId><ArticleId IdType="pubmed">32289277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Zhou D, Wang L, et al. MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:1543990599. doi:10.1177/20406207211072839</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406207211072839</ArticleId><ArticleId IdType="pmc">PMC8808040</ArticleId><ArticleId IdType="pubmed">35126963</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643&#x2013;1653. doi:10.1016/j.ccell.2021.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8722194</ArticleId><ArticleId IdType="pubmed">34739844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>